{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Robbins HA"],"funding":["NEI NIH HHS","NIA NIH HHS","NHLBI NIH HHS","NCI NIH HHS","WHI NIH HHS"],"pagination":["1-12"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9835888"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["77"],"pubmed_abstract":["The Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) program is an NCI-funded initiative with an objective to develop tools to optimize low-dose CT (LDCT) lung cancer screening. Here, we describe the rationale and design for the Risk Biomarker and Nodule Malignancy projects within INTEGRAL. The overarching goal of these projects is to systematically investigate circulating protein markers to include on a panel for use (i) pre-LDCT, to identify people likely to benefit from screening, and (ii) post-LDCT, to differentiate benign versus malignant nodules. To identify informative proteins, the Risk Biomarker project measured 1161 proteins in a nested-case control study within 2 prospective cohorts (n = 252 lung cancer cases and 252 controls) and replicated associations for a su"],"journal":["Annals of epidemiology"],"pubmed_title":["Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program."],"pmcid":["PMC9835888"],"funding_grant_id":["U01 CA086308","UM1 CA182913","R01 HL043851","P50 CA090440","R01 CA251758","R01 CA034944","R01 CA047988","R01 HL080467","R01 HL026490","U01 CA182913","P30 CA006973","75N92021D00001","U01 CA202979","75N92021D00002","75N92021D00003","75N92021D00004","R01 CA097193","75N92021D00005","R01 CA040360","P30 CA047904","R03 CA245979","R01 HL034595","RC1 HL099355","R01 EY018820","U19 CA203654","U01 AG018033"],"pubmed_authors":["Berg CD","Huang WY","Montuenga LM","Sesso HD","Guida F","Malekzadeh R","Alcala K","Brhane Y","Amos CI","Aldrich MC","Wang R","Bassett J","Visvanathan K","Langhammer A","Freedman ND","Warkentin MT","Wang Y","Moez EK","Brennan P","Milne RL","Feng X","Liao LM","Chen C","Zheng W","Arslan AA","Jones M","Sinha R","Lan Q","Muller D","Field JK","Cai Q","Diergaarde B","Severi G","Weinstein SJ","Koh WP","Thomas S","Zahed H","Hung RJ","White E","Rohan T","Yuan JM","Shu XO","Tinker LF","Tammemagi MC","Albanes D","Wilson D","Smith-Byrne K","Lam S","Zhang X","Davies MPA","Johansson M","Stevens VL","Robbins HA","Liu G","Sheikh M"],"additional_accession":[]},"is_claimable":false,"name":"Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program.","description":"The Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) program is an NCI-funded initiative with an objective to develop tools to optimize low-dose CT (LDCT) lung cancer screening. Here, we describe the rationale and design for the Risk Biomarker and Nodule Malignancy projects within INTEGRAL. The overarching goal of these projects is to systematically investigate circulating protein markers to include on a panel for use (i) pre-LDCT, to identify people likely to benefit from screening, and (ii) post-LDCT, to differentiate benign versus malignant nodules. To identify informative proteins, the Risk Biomarker project measured 1161 proteins in a nested-case control study within 2 prospective cohorts (n = 252 lung cancer cases and 252 controls) and replicated associations for a su","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-04T13:53:12.627Z","creation":"2025-04-04T13:53:12.627Z"},"accession":"S-EPMC9835888","cross_references":{"pubmed":["36404465"],"doi":["10.1016/j.annepidem.2022.10.014"]}}